Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
about
Lupus nephritis: the evolving role of novel therapeuticsThe pathogenesis, diagnosis and treatment of lupus nephritis.Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin OncologyInformative gene network for chemotherapy-induced peripheral neuropathyEuropean perspective on multiple myeloma treatment strategies: update following recent congressesA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaPhytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Bortezomib-induced peripheral neurotoxicity: an update.Chemotherapy-induced peripheral neuropathies in hematological malignancies.Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.An Overview of Bortezomib-Induced NeurotoxicityBortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyClinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain
P2860
Q26998390-455EACEF-740B-4091-B04E-4F6F629366EEQ30596968-4ADCFF9A-4CD1-4F19-A7EF-B2D4BBCE4233Q34245549-63ACC83A-E641-4FA8-B4F2-5A52CB7F0B09Q35945680-307A9739-AE78-41F5-9B51-F2F5C0F8AEC5Q35989943-0D3C4A29-8950-4EC5-B165-A7DCE610983DQ36671445-C300F431-2B9D-4C0D-84EE-CB221C424A57Q37275721-494E7AD1-5344-4464-AFB5-49EA3DA82A29Q37659699-A9D6F9BD-101F-4847-BED3-892381559738Q38234733-8E3048F3-BAB5-459D-8556-1CDB57151725Q38261204-C3C7946B-DFEC-4DD9-B13A-EC743209EFFEQ38664595-C889A28E-78A9-4096-90C4-54454010033AQ39597050-AD5B77DB-D88A-4F19-8BC0-10455DC02CD0Q40286050-2AA36487-C267-454E-843C-9C1BE22E9CA0Q41009823-FC0D0F2A-9860-4CD5-9E4D-868F8F41BA07Q42361419-FA494570-14C8-42F7-9F7B-7933E9227BD1Q43444151-45950116-3B3D-463D-8DA0-7F148606282BQ48682753-8EFE70CF-235C-4DAD-BCB3-C3E32E54A27DQ55279720-DB7749CF-175E-4AFC-A5DE-BF8A2A52E6EFQ56971945-56A9DF03-D231-4911-A2A3-B54A09EC85C4Q58699248-4F0AA8B3-C818-46F5-9845-E60BE4AAB3A3
P2860
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic factors underlying the ...... in multiple myeloma patients.
@ast
Genetic factors underlying the ...... in multiple myeloma patients.
@en
type
label
Genetic factors underlying the ...... in multiple myeloma patients.
@ast
Genetic factors underlying the ...... in multiple myeloma patients.
@en
prefLabel
Genetic factors underlying the ...... in multiple myeloma patients.
@ast
Genetic factors underlying the ...... in multiple myeloma patients.
@en
P2093
P2860
P50
P1433
P1476
Genetic factors underlying the ...... in multiple myeloma patients.
@en
P2093
Bronno van der Holt
David C Johnson
Gareth J Morgan
Roman Hajek
Rowan Kuiper
Sophie L Corthals
P2860
P304
P356
10.3324/HAEMATOL.2011.041434
P577
2011-07-26T00:00:00Z